Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 2 , Pages vii-ix , April 2008

Preface

  • Fernand Labrie, OC, OQ, MD, PhD, FRCPC (Director)

      Affiliations

    • Corresponding Author InformationTel.: +1 418 654 2296; Fax: +1 418 654 2761.

References 

  1. Labrie F, Candas B, Cusan L, et al. Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen. Urology. 1996;47:212–217
  2. Labrie F, Candas B, Gomez JL, et al. Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer?. Urology. 2002;60(1):115–119
  3. Fleshner N, Keane TE, Lawton CA, et al. Adjuvant androgen deprivation therapy augments cure and long-term cancer control in men with poor prognosis, nonmetastatic prostate cancer. Prostate Cancer and Prostatic Diseases. 2007;
  4. Peto R, Dalesio O. Breast and prostate cancer: 10-year survival gains in the hormonal adjuvant treatment trials. ECCO. European Journal of Cancer. 2003;12:S101;Copenhagen
  5. Labrie F, Dupont A, Bélanger A. Complete androgen blockade for the treatment of prostate cancer. In:  de Vita VT,  Hellman S,  Rosenberg SA editor. Important Advances in Oncology. Philadelphia: J.B. Lippincott; 1985;p. 193–217
  6. Labrie F. Multiple intracrine hormonal targets in the prostate: opportunities and challenges. BJU International. 2007;100(Suppl 2):48–51
  7. Labrie C, Simard J, Zhao HF, et al. Stimulation of androgen-dependent gene expression by the adrenal precursors dehydroepiandrosterone and androstenedione in the rat ventral prostate. Endocrinology. 1989;124:2745–2754
  8. Labrie F. Intracrinology. Molecular and Cellular Endocrinology. 1991;78:C113–C118

PII: S1521-690X(08)00034-1

doi: 10.1016/j.beem.2008.02.005

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 2 , Pages vii-ix , April 2008

Article Tools